REFERENCES
- Kastner A, Hirsch EC, Agid Y, Javoy-Agid F. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease. Brain Res 1993; 606: 341–345
- Barr E, Leiden JM. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 1991; 254: 1507-1509
- Beck KD, Knusel B, Hefti F. The nature of the trophic action of brain-derived neurotrophic factor, des (1-3)-insulin-tile growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience 1993; 52: 855–866
- Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350: 230–232
- Otto D, Unsicker K. Basic FGF reverses chemical and morpho-logical deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci 1990; 10: 1912–1921
- Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM Jr, Milbrandt J. Neurturin, a relative of gl ial-cell-lire-derived neurotrophic factor. Nature 1996; 384: 467–470
- Bezard E, Dovero S, Bioulac B, Gross C. Effects of different schedules of MPTP administration on dopaminergic neurodegen-eration in mice. Exp Neurol 1997; 148: 288–292.
- Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE. Comparison of eight clinical rating scales used for the assessment of MPTP-induced Parkinsonism in the Macaque monkey.] Neurosci Meth 2000; 96: 71–76
- Miller FP, Cox RH Jr, Maickel RP. The effects of altered brain norepinephrine levels on continuous avoidance responding and the action of amphetamines. Neuropharmacology 1970; 9: 511–517
- Willner P. Dopamineand depression:A review of recent evidence. I. Empirical studies. Brain Res 1983; 287: 211–224
- Baloh RH, Tansey MG, Lampe PA, Fahrner Ti, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM Jr, Milbrandt J. Artem in, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 1998; 21: 1291–1302
- Saarma M, Sariola H. Other neurotrophic factors: Glial cell line-derived neurotrophic factor (GDNF). Microsc Res Tech 1999; 45: 292–302
- Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L. Protection and repair of the nigrostriatal dopam inergic system by GDNF in vivo. Nature 1995; 373: 335–339
- Li Hi, Ma YB, Dai CB, Sun MS. Construction of neurturin fusion expression vector with hydroxylamine site and purification and bioactivity of expressive products. Chin] Biochem Mol Biol 2001; 17: 139–142
- Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980
- Langston JW, Ballard PA Jr. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 1983; 309: 310
- Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinson ism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Proc Natl Acad Sci USA 1983; 80: 4546–4550
- Hallman H, Lange J, Olson L, Stromberg I, Jonsson G. Neuro-chem ica I and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridire on brain cate-cholamine neurones in the mouse. J Neurochem 1985; 44: 117–127
- Russ H, Mihatsch W, Gerlach M, Riederer P, Przuntek H. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease? Neurosci Lett 1991; 123: 115–118
- Irwin I, DeLanney LE, Forno LS, Finnegan KT, Di Monte DA, Langston JW. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res 1990; 531: 242–252
- Stern Y. MPTP-induced parkinsonism. Prog Neurobiol 1990; 34: 107–114
- Tolwani RJ, Jakowec MW, Petzinger GM, Green S, Waggie K. Experimental models of Parkinson's disease: Insights from many models. Lab Anim Sci 1999; 49: 363–371